$TOVX
Theriva Biologics, Inc.

2018 Q1 Form 10-Q Financial Statement

#000114420418026171 Filed on May 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.620M $2.090M
YoY Change -22.49% -13.99%
% of Gross Profit
Research & Development $3.370M $6.059M
YoY Change -44.38% -25.7%
% of Gross Profit
Depreciation & Amortization $71.00K $57.00K
YoY Change 24.56% 54.05%
% of Gross Profit
Operating Expenses $4.990M $8.149M
YoY Change -38.77% -0.07%
Operating Profit -$4.990M -$8.149M
YoY Change -38.77% -22.98%
Interest Expense $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.664M $5.091M
YoY Change -47.67% -1124.35%
Pretax Income -$4.990M -$8.149M
YoY Change -38.77% -22.98%
Income Tax
% Of Pretax Income
Net Earnings -$2.316M -$3.058M
YoY Change -24.26% -72.4%
Net Earnings / Revenue
Basic Earnings Per Share -$0.65 -$0.70
Diluted Earnings Per Share -$0.65 -$0.70
COMMON SHARES
Basic Shares Outstanding 3.673M 3.356M
Diluted Shares Outstanding 3.673M 3.356M

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.04M $13.47M
YoY Change -18.04% -10.79%
Cash & Equivalents $11.04M $13.47M
Short-Term Investments
Other Short-Term Assets $610.0K $175.0K
YoY Change 248.57% -97.54%
Inventory
Prepaid Expenses $104.0K
Receivables
Other Receivables $0.00
Total Short-Term Assets $11.64M $16.84M
YoY Change -30.88% -24.21%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $860.0K
YoY Change -6.98% 72.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $20.00K
YoY Change 0.0% -33.33%
Total Long-Term Assets $830.0K $880.0K
YoY Change -5.68% 69.23%
TOTAL ASSETS
Total Short-Term Assets $11.64M $16.84M
Total Long-Term Assets $830.0K $880.0K
Total Assets $12.47M $17.72M
YoY Change -29.63% -22.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.490M $3.800M
YoY Change -60.79% -17.39%
Accrued Expenses $2.070M $2.920M
YoY Change -29.11% 60.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.090M $16.49M
YoY Change -69.13% -5.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $380.0K $470.0K
YoY Change -19.15% 95.83%
Total Long-Term Liabilities $380.0K $470.0K
YoY Change -19.15% 95.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.090M $16.49M
Total Long-Term Liabilities $380.0K $470.0K
Total Liabilities $3.540M $15.15M
YoY Change -76.63% -8.13%
SHAREHOLDERS EQUITY
Retained Earnings -$196.5M
YoY Change
Common Stock $193.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.186M $2.570M
YoY Change
Total Liabilities & Shareholders Equity $12.47M $17.72M
YoY Change -29.64% -22.08%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.316M -$3.058M
YoY Change -24.26% -72.4%
Depreciation, Depletion And Amortization $71.00K $57.00K
YoY Change 24.56% 54.05%
Cash From Operating Activities -$6.079M -$6.008M
YoY Change 1.18% 5.89%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $11.00K
YoY Change -100.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$11.00K
YoY Change -100.0% -75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $435.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -6.079M -$6.008M
Cash From Investing Activities 0.000 -$11.00K
Cash From Financing Activities 0.000 $435.0K
Net Change In Cash -6.079M -$5.584M
YoY Change 8.86% -2.34%
FREE CASH FLOW
Cash From Operating Activities -$6.079M -$6.008M
Capital Expenditures $0.00 $11.00K
Free Cash Flow -$6.079M -$6.019M
YoY Change 1.0% 5.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-2326000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6059000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5090000 USD
CY2018Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-10000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4990000 USD
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2664000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
59000 USD
CY2017Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2375000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2846000 USD
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
128566883 shares
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-3058000 USD
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
377000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
402000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
4990000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
129000 USD
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193230000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196545000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-3186000 USD
CY2018Q1 us-gaap Minority Interest
MinorityInterest
-1923000 USD
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5109000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12467000 USD
CY2018Q1 syn Warrant Liabilities
WarrantLiabilities
1428000 USD
CY2017Q4 syn Warrant Liabilities
WarrantLiabilities
4083000 USD
CY2018Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1016000 USD
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2074000 USD
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
92000 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
90000 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
117447260 shares
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1135000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-493000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6008000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19055000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13471000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
15000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
676000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-527000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6079000 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2018Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-6079000 USD
CY2018Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1058000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
71000 USD
CY2018Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
98000 USD
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
500000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
429000 USD
CY2018Q1 syn Accrued Vendor Payments
AccruedVendorPayments
376000 USD
CY2017Q4 syn Accrued Vendor Payments
AccruedVendorPayments
193000 USD
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14000 USD
CY2018Q1 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
55000 USD
CY2017Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
661000 USD
CY2018Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
336000 USD
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1283000 USD
CY2018Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
268000 USD
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
201000 USD
CY2018Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
412000 USD
CY2017Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
590000 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2074000 USD
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000 USD
CY2018Q1 us-gaap Share Price
SharePrice
0.32
CY2017Q4 us-gaap Share Price
SharePrice
0.51
CY2018Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2018Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8 pure
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8 pure
CY2018Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0219 pure
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0186 pure
CY2018Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y6M18D
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y9M14D
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
32054809 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.5
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.52
CY2018Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2018Q1 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2017Q1 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2316000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2846000 USD
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128566883 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117447260 shares
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128566883 shares
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117447260 shares
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2017Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2018Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2018Q1 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.885 pure
CY2018Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.02 pure
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128648365 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128566886 shares
CY2018Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
9000 USD
CY2017Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2017 syn Deferred Tax Assetsfederal And Statutory Income Tax Rate
DeferredTaxAssetsfederalAndStatutoryIncomeTaxRate
0.21 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
21600000 USD
CY2018Q1 us-gaap Prepaid Insurance
PrepaidInsurance
237000 USD
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
351000 USD
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
104000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
94000 USD
CY2018Q1 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
0 USD
CY2017Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
46000 USD
CY2018Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 USD
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
46000 USD
CY2018Q1 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
265000 USD
CY2017Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
290000 USD
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1301000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1301000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000 USD
CY2017Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
73000 USD
CY2018Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
59000 USD
CY2016Q4 us-gaap Share Price
SharePrice
1.75
CY2016Q4 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2016Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0139 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2017Q4 us-gaap Share Price
SharePrice
0.53
CY2017Q4 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.85 pure
CY2017Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0242 pure
CY2017Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y11M1D
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
269000 USD
CY2018Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
0 USD
CY2017Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
166000 USD
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6900000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
32029809 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.50
CY2017Q4 syn Consulting Agreement Term
ConsultingAgreementTerm
P6M

Files In Submission

Name View Source Status
0001144204-18-026171-index-headers.html Edgar Link pending
0001144204-18-026171-index.html Edgar Link pending
0001144204-18-026171.txt Edgar Link pending
0001144204-18-026171-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20180331.xml Edgar Link completed
syn-20180331.xsd Edgar Link pending
syn-20180331_cal.xml Edgar Link unprocessable
syn-20180331_def.xml Edgar Link unprocessable
syn-20180331_lab.xml Edgar Link unprocessable
syn-20180331_pre.xml Edgar Link unprocessable
tv492231_10q.htm Edgar Link pending
tv492231_ex31-1.htm Edgar Link pending
tv492231_ex32-1.htm Edgar Link pending
tv492231_ex4-1.htm Edgar Link pending
tv492231_img1.jpg Edgar Link pending